Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology at Hannover Medical School, shared a post on X:
“CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer
based on HERIZON-BTC: ORR 41%
Phs-III in 1st line ongoing
More posts featuring biliary tract cancer.